Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Biology and management of primary effusion lymphoma.

Shimada K, Hayakawa F, Kiyoi H.

Blood. 2018 Aug 28. pii: blood-2018-03-791426. doi: 10.1182/blood-2018-03-791426. [Epub ahead of print]

PMID:
30154110
2.

Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.

Takeshita A, Asou N, Atsuta Y, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Furumaki H, Obata Y, Fujita H, Yanada M, Maeda Y, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Matsumura I, Naoe T, Miyazaki Y; and the Japanese Adult Leukemia Study Group.

Leukemia. 2018 Aug 9. doi: 10.1038/s41375-018-0233-7. [Epub ahead of print]

PMID:
30093681
3.

Impact of hospital length of stay on the risk of readmission and overall survival after allogeneic stem cell transplantation.

Seto A, Atsuta Y, Kawashima N, Ozawa Y, Miyamura K, Kiyoi H.

Int J Hematol. 2018 Jun 19. doi: 10.1007/s12185-018-2477-4. [Epub ahead of print]

PMID:
29923123
4.

Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols.

Kato H, Fujita H, Akiyama N, Kimura SI, Hiramoto N, Hosono N, Takahashi T, Shigeno K, Minamiguchi H, Miyatake J, Handa H, Kanda Y, Yoshida M, Miyawaki S, Ohtake S, Naoe T, Kiyoi H, Matsumura I, Miyazaki Y; Japan Adult Leukemia Study Group.

Support Care Cancer. 2018 Jun 2. doi: 10.1007/s00520-018-4292-0. [Epub ahead of print]

PMID:
29860713
5.

Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell Response.

Ueda N, Uemura Y, Zhang R, Kitayama S, Iriguchi S, Kawai Y, Yasui Y, Tatsumi M, Ueda T, Liu TY, Mizoro Y, Okada C, Watanabe A, Nakanishi M, Senju S, Nishimura Y, Kuzushima K, Kiyoi H, Naoe T, Kaneko S.

Stem Cell Reports. 2018 Jun 5;10(6):1935-1946. doi: 10.1016/j.stemcr.2018.04.025. Epub 2018 May 24.

6.

Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia.

Tanaka Y, Kawazu M, Yasuda T, Tamura M, Hayakawa F, Kojima S, Ueno T, Kiyoi H, Naoe T, Mano H.

Haematologica. 2018 May 17. pii: haematol.2017.183152. doi: 10.3324/haematol.2017.183152. [Epub ahead of print] No abstract available.

7.

Phase I study of cord blood transplantation with intrabone marrow injection of mesenchymal stem cells: A clinical study protocol.

Goto T, Murata M, Terakura S, Nishida T, Adachi Y, Ushijima Y, Shimada K, Ishikawa Y, Hayakawa F, Nishio N, Nishiwaki S, Hirakawa A, Kato K, Takahashi Y, Kiyoi H.

Medicine (Baltimore). 2018 Apr;97(17):e0449. doi: 10.1097/MD.0000000000010449.

8.

Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.

Hatta Y, Mizuta S, Matsuo K, Ohtake S, Iwanaga M, Sugiura I, Doki N, Kanamori H, Ueda Y, Yoshida C, Dobashi N, Maeda T, Yujiri T, Monma F, Ito Y, Hayakawa F, Takeuchi J, Kiyoi H, Miyazaki Y, Naoe T.

Ann Hematol. 2018 Sep;97(9):1535-1545. doi: 10.1007/s00277-018-3323-8. Epub 2018 Apr 24.

9.

Mutation analysis of therapy-related myeloid neoplasms.

Nishiyama T, Ishikawa Y, Kawashima N, Akashi A, Adachi Y, Hattori H, Ushijima Y, Kiyoi H.

Cancer Genet. 2018 Apr;222-223:38-45. doi: 10.1016/j.cancergen.2018.02.006. Epub 2018 Mar 8.

PMID:
29666007
10.

Introduction of Genetically Modified CD3ΞΆ Improves Proliferation and Persistence of Antigen-Specific CTLs.

Miyao K, Terakura S, Okuno S, Julamanee J, Watanabe K, Hamana H, Kishi H, Sakemura R, Koyama D, Goto T, Nishida T, Murata M, Kiyoi H.

Cancer Immunol Res. 2018 Jun;6(6):733-744. doi: 10.1158/2326-6066.CIR-17-0538. Epub 2018 Apr 13.

PMID:
29653982
11.

[MonoMAC syndrome patient developing myelodysplastic syndrome following persistent EBV infection].

Yamamoto H, Hattori H, Takagi E, Morishita T, Ishikawa Y, Terakura S, Nishida T, Ito Y, Murata M, Kiyoi H.

Rinsho Ketsueki. 2018;59(3):315-322. doi: 10.11406/rinketsu.59.315. Japanese.

PMID:
29618691
12.

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.

Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, Takagi H, Hagiwara D, Ito Y, Morishita Y, Goto M, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Arima H.

J Endocr Soc. 2018 Feb 6;2(3):241-251. doi: 10.1210/js.2017-00432. eCollection 2018 Mar 1.

13.

Analysis of the oligomeric states of nucleophosmin using size exclusion chromatography.

Sakashita G, Kiyoi H, Naoe T, Urano T.

Sci Rep. 2018 Mar 5;8(1):4008. doi: 10.1038/s41598-018-22359-w.

14.

Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200.

Harada K, Doki N, Miyazaki Y, Wakita A, Ohtake S, Takada S, Komatsu H, Kubo K, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Naoe T, Ohashi K.

Ann Hematol. 2018 Aug;97(8):1481-1483. doi: 10.1007/s00277-018-3281-1. Epub 2018 Mar 1. No abstract available.

PMID:
29497807
15.

Efficacy and safety of autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: A study protocol for a multicenter exploratory prospective study (Auto-Ph17 study).

Nishiwaki S, Sugiura I, Miyata Y, Saito S, Sawa M, Nishida T, Miyamura K, Kuwatsuka Y, Kohno A, Yuge M, Kasai M, Iida H, Kurahashi S, Osaki M, Goto T, Terakura S, Murata M, Nishikawa H, Kiyoi H.

Medicine (Baltimore). 2017 Dec;96(52):e9568. doi: 10.1097/MD.0000000000009568.

16.

Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.

Harada Y, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Onizuka M, Takeshita A, Ishida F, Suzushima H, Ishizawa K, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group JALSG.

Leuk Res. 2018 Mar;66:20-27. doi: 10.1016/j.leukres.2018.01.008. Epub 2018 Jan 17.

PMID:
29360622
17.

Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia.

Kamijo R, Itonaga H, Kihara R, Nagata Y, Hata T, Asou N, Ohtake S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T, Kiyoi H, Miyazaki Y.

Leuk Res. 2018 Feb;65:34-41. doi: 10.1016/j.leukres.2017.12.006. Epub 2018 Jan 2.

PMID:
29306105
18.

Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.

Harada K, Doki N, Hagino T, Miyawaki S, Ohtake S, Kiyoi H, Miyazaki Y, Fujita H, Usui N, Okumura H, Miyamura K, Nakaseko C, Fujieda A, Nagai T, Yamane T, Sakamaki H, Ohnishi K, Naoe T, Ohno R, Ohashi K.

Ann Hematol. 2018 Jan;97(1):73-81. doi: 10.1007/s00277-017-3156-x. Epub 2017 Dec 2.

PMID:
29196987
19.

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.

Yamaura T, Nakatani T, Uda K, Ogura H, Shin W, Kurokawa N, Saito K, Fujikawa N, Date T, Takasaki M, Terada D, Hirai A, Akashi A, Chen F, Adachi Y, Ishikawa Y, Hayakawa F, Hagiwara S, Naoe T, Kiyoi H.

Blood. 2018 Jan 25;131(4):426-438. doi: 10.1182/blood-2017-05-786657. Epub 2017 Nov 29.

PMID:
29187377
20.

Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.

Shirahata-Adachi M, Iriyama C, Tomita A, Suzuki Y, Shimada K, Kiyoi H.

Leuk Res. 2017 Dec;63:90-97. doi: 10.1016/j.leukres.2017.10.015. Epub 2017 Nov 4.

PMID:
29127861
21.

Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia.

Adachi Y, Ishikawa Y, Kiyoi H.

Oncotarget. 2017 Jul 26;8(45):78452-78465. doi: 10.18632/oncotarget.19632. eCollection 2017 Oct 3.

22.

Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.

Kuwatsuka Y, Tomizawa D, Kihara R, Nagata Y, Shiba N, Iijima-Yamashita Y, Shimada A, Deguchi T, Miyachi H, Tawa A, Taga T, Kinoshita A, Nakayama H, Kiyokawa N, Saito AM, Koh K, Goto H, Kosaka Y, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Ogawa S, Naoe T, Hayashi Y, Horibe K, Manabe A, Mizutani S, Adachi S, Kiyoi H.

Int J Hematol. 2018 Feb;107(2):201-210. doi: 10.1007/s12185-017-2340-z. Epub 2017 Oct 12.

PMID:
29027108
23.

High incidence of extensive chronic graft-versus-host disease in patients with the REG3A rs7588571 non-GG genotype.

Koyama D, Murata M, Hanajiri R, Okuno S, Kamoshita S, Julamanee J, Takagi E, Hirano D, Miyao K, Sakemura R, Goto T, Hayakawa F, Seto A, Ozawa Y, Miyamura K, Terakura S, Nishida T, Kiyoi H.

PLoS One. 2017 Sep 25;12(9):e0185213. doi: 10.1371/journal.pone.0185213. eCollection 2017.

24.

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, Miyata Y, Kobayashi S, Usuki K, Matsumura I, Minami Y, Usui N, Fukuda T, Takada S, Ishikawa M, Fujimaki K, Gomyo H, Sasaki O, Ohishi K, Miyake T, Imai K, Suzushima H, Mitsui H, Togitani K, Kiguchi T, Atsuta Y, Ohtake S, Ohnishi K, Kobayashi Y, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group.

Int J Hematol. 2018 Feb;107(2):185-193. doi: 10.1007/s12185-017-2334-x. Epub 2017 Sep 19.

PMID:
28929332
25.

High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG.

Sakura T, Hayakawa F, Sugiura I, Murayama T, Imai K, Usui N, Fujisawa S, Yamauchi T, Yujiri T, Kakihana K, Ito Y, Kanamori H, Ueda Y, Miyata Y, Kurokawa M, Asou N, Ohnishi K, Ohtake S, Kobayashi Y, Matsuo K, Kiyoi H, Miyazaki Y, Naoe T.

Leukemia. 2018 Mar;32(3):626-632. doi: 10.1038/leu.2017.283. Epub 2017 Sep 15.

PMID:
28914260
26.

A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).

Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M; for National Research Group on Idiopathic Bone Marrow Failure Syndromes.

Am J Hematol. 2017 Dec;92(12):1324-1332. doi: 10.1002/ajh.24905. Epub 2017 Sep 28.

PMID:
28891083
27.

Clinical effectiveness of geriatric assessment for predicting the tolerability of outpatient chemotherapy in older adults with cancer.

Hayashi N, Matsuoka A, Goto H, Gotoh M, Kiyoi H, Kodera Y, Nagino M, Nagashima F, Ando Y.

J Geriatr Oncol. 2018 Jan;9(1):84-86. doi: 10.1016/j.jgo.2017.07.014. Epub 2017 Aug 9. No abstract available.

PMID:
28802840
28.

Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group.

Kimura SI, Fujita H, Kato H, Hiramoto N, Hosono N, Takahashi T, Shigeno K, Hatsumi N, Minamiguchi H, Miyatake J, Handa H, Akiyama N, Kanda Y, Yoshida M, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group (JALSG).

Support Care Cancer. 2017 Nov;25(11):3515-3521. doi: 10.1007/s00520-017-3775-8. Epub 2017 Jun 6.

PMID:
28584934
29.

Phase II study of intrabone single unit cord blood transplantation for hematological malignancies.

Murata M, Maeda Y, Masuko M, Onishi Y, Endo T, Terakura S, Ishikawa Y, Iriyama C, Ushijima Y, Goto T, Fujii N, Tanimoto M, Kobayashi H, Shibasaki Y, Fukuhara N, Inamoto Y, Suzuki R, Kodera Y, Matsushita T, Kiyoi H, Naoe T, Nishida T.

Cancer Sci. 2017 Aug;108(8):1634-1639. doi: 10.1111/cas.13291. Epub 2017 Jun 29.

30.

[I.Genetic Abnormalities Associated with Acute Leukemia and a Development of Molecular Therapies].

Adachi Y, Kiyoi H.

Gan To Kagaku Ryoho. 2017 May;44(5):380-385. Japanese. No abstract available.

PMID:
28536332
31.

Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.

Togasaki E, Takeda J, Yoshida K, Shiozawa Y, Takeuchi M, Oshima M, Saraya A, Iwama A, Yokote K, Sakaida E, Hirase C, Takeshita A, Imai K, Okumura H, Morishita Y, Usui N, Takahashi N, Fujisawa S, Shiraishi Y, Chiba K, Tanaka H, Kiyoi H, Ohnishi K, Ohtake S, Asou N, Kobayashi Y, Miyazaki Y, Miyano S, Ogawa S, Matsumura I, Nakaseko C, Naoe T.

Blood Cancer J. 2017 Apr 28;7(4):e559. doi: 10.1038/bcj.2017.36.

32.

YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma.

Kojima Y, Hayakawa F, Morishita T, Sugimoto K, Minamikawa Y, Iwase M, Yamamoto H, Hirano D, Imoto N, Shimada K, Okada S, Kiyoi H.

Pharmacol Res. 2017 Jun;120:242-251. doi: 10.1016/j.phrs.2017.04.006. Epub 2017 Apr 8.

PMID:
28396094
33.

Malignant lymphoma with cardiac involvement.

Terakura S, Onji M, Iriyama C, Goto T, Ushijima Y, Shimada K, Ishikawa Y, Nishida T, Hayakawa F, Murata M, Kiyoi H.

Rinsho Ketsueki. 2017;58(3):239-242. doi: 10.11406/rinketsu.58.239. Japanese.

PMID:
28381692
34.

Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study.

Yokohata E, Kuwatsuka Y, Ohashi H, Terakura S, Kawashima N, Seto A, Kurahashi S, Ozawa Y, Goto T, Imahashi N, Nishida T, Miyao K, Sakemura R, Kato T, Sawa M, Kohno A, Sao H, Iida H, Kiyoi H, Naoe T, Miyamura K, Murata M.

Bone Marrow Transplant. 2017 Apr;52(4):612-614. doi: 10.1038/bmt.2016.323. Epub 2017 Jan 9. No abstract available.

PMID:
28067879
35.

Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism.

Aoki T, Shimada K, Sakamoto A, Sugimoto K, Morishita T, Kojima Y, Shimada S, Kato S, Iriyama C, Kuno S, Harada Y, Tomita A, Hayakawa F, Kiyoi H.

Oncotarget. 2017 Feb 21;8(8):13085-13098. doi: 10.18632/oncotarget.14393.

36.

Corrigendum: Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.

Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H.

Nat Genet. 2016 Nov 29;48(12):1591. doi: 10.1038/ng1216-1587a. No abstract available.

PMID:
27898077
37.

Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms.

Mori T, Nagata Y, Makishima H, Sanada M, Shiozawa Y, Kon A, Yoshizato T, Sato-Otsubo A, Kataoka K, Shiraishi Y, Chiba K, Tanaka H, Ishiyama K, Miyawaki S, Mori H, Nakamaki T, Kihara R, Kiyoi H, Koeffler HP, Shih LY, Miyano S, Naoe T, Haferlach C, Kern W, Haferlach T, Ogawa S, Yoshida K.

Leukemia. 2016 Nov;30(11):2270-2273. doi: 10.1038/leu.2016.212. Epub 2016 Aug 1. No abstract available.

PMID:
27479181
38.

Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells.

Fukushima N, Minami Y, Kakiuchi S, Kuwatsuka Y, Hayakawa F, Jamieson C, Kiyoi H, Naoe T.

Cancer Sci. 2016 Oct;107(10):1422-1429. doi: 10.1111/cas.13019. Epub 2016 Sep 2.

39.

Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device.

Matsuoka A, Mitsuma A, Maeda O, Kajiyama H, Kiyoi H, Kodera Y, Nagino M, Goto H, Ando Y.

Cancer Sci. 2016 Oct;107(10):1453-1457. doi: 10.1111/cas.13010. Epub 2016 Sep 2.

40.

Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study.

Suzuki N, Hirakawa A, Kishimoto M, Kanematsu T, Ogawa M, Kiyoi H, Matsushita T.

Haemophilia. 2017 Mar;23(2):215-221. doi: 10.1111/hae.13082. Epub 2016 Oct 5.

PMID:
27704637
41.

Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.

Goto T, Nishida T, Takagi E, Miyao K, Koyama D, Sakemura R, Hanajiri R, Watanabe K, Imahashi N, Terakura S, Murata M, Kiyoi H.

J Immunother. 2016 Oct;39(8):306-15. doi: 10.1097/CJI.0000000000000136.

PMID:
27548033
42.

The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib.

Morishita T, Hayakawa F, Sugimoto K, Iwase M, Yamamoto H, Hirano D, Kojima Y, Imoto N, Naoe T, Kiyoi H.

Oncotarget. 2016 Aug 30;7(35):56241-56252. doi: 10.18632/oncotarget.11025.

43.

SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway.

Takagi Y, Shimada K, Shimada S, Sakamoto A, Naoe T, Nakamura S, Hayakawa F, Tomita A, Kiyoi H.

Cancer Sci. 2016 Sep;107(9):1270-80. doi: 10.1111/cas.13001. Epub 2016 Sep 6.

44.

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells.

Chen F, Ishikawa Y, Akashi A, Naoe T, Kiyoi H.

Oncotarget. 2016 Jul 26;7(30):47018-47032. doi: 10.18632/oncotarget.10147.

45.

A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.

Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K, Koyama D, Goto T, Hanajiri R, Nishida T, Murata M, Kiyoi H.

Cancer Immunol Res. 2016 Aug;4(8):658-68. doi: 10.1158/2326-6066.CIR-16-0043. Epub 2016 Jun 21.

46.

Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes.

Suzuki Y, Tomita A, Nakamura F, Iriyama C, Shirahata-Adachi M, Shimada K, Akashi A, Ishikawa Y, Kaneda N, Kiyoi H.

Cancer Sci. 2016 Sep;107(9):1329-37. doi: 10.1111/cas.12994. Epub 2016 Aug 25.

47.

Live-cell single-molecule imaging of the cytokine receptor MPL for analysis of dynamic dimerization.

Sakamoto A, Tsukamoto T, Furutani Y, Sudo Y, Shimada K, Tomita A, Kiyoi H, Kato T, Funatsu T.

J Mol Cell Biol. 2016 Dec;8(6):553-555. Epub 2016 Jun 9. No abstract available.

PMID:
27282404
48.

PAX5 tyrosine phosphorylation by SYK co-operatively functions with its serine phosphorylation to cancel the PAX5-dependent repression of BLIMP1: A mechanism for antigen-triggered plasma cell differentiation.

Inagaki Y, Hayakawa F, Hirano D, Kojima Y, Morishita T, Yasuda T, Naoe T, Kiyoi H.

Biochem Biophys Res Commun. 2016 Jun 24;475(2):176-81. doi: 10.1016/j.bbrc.2016.05.067. Epub 2016 May 13.

PMID:
27181361
49.

BCR-ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells.

Ueda N, Zhang R, Tatsumi M, Liu TY, Kitayama S, Yasui Y, Sugai S, Iwama T, Senju S, Okada S, Nakatsura T, Kuzushima K, Kiyoi H, Naoe T, Kaneko S, Uemura Y.

Cell Mol Immunol. 2018 Jan;15(1):15-26. doi: 10.1038/cmi.2016.7. Epub 2016 May 15.

PMID:
27181332
50.

Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.

Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H.

Nat Genet. 2016 May;48(5):569-74. doi: 10.1038/ng.3535. Epub 2016 Mar 28. Erratum in: Nat Genet. 2016 Nov 29;48(12 ):1591.

PMID:
27019113

Supplemental Content

Support Center